Additionally, CRISPR-mediated knockdown of PDCD1 (which encodes PD1) in CAR-T cells has demonstrated enhanced CAR-T cell performance in both B cell and solid tumor models, resulting in improved in vivo anti-tumor responses (200, 201). The gene discussed is PDCD1; the disease is neoplasm.